Prasugrel + Clopidogrel
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction, STEMI
Trial Timeline
May 1, 2011 → Jul 1, 2013
NCT ID
NCT01327534About Prasugrel + Clopidogrel
Prasugrel + Clopidogrel is a phase 3 stage product being developed by Daiichi Sankyo for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT01327534. Target conditions include Myocardial Infarction, STEMI.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01327534 | Phase 3 | Completed |
| NCT01260584 | Approved | Completed |
| NCT01107912 | Phase 1 | Completed |
| NCT01107925 | Phase 1 | Completed |
| NCT01014624 | Approved | Completed |
| NCT00910299 | Phase 2 | Terminated |
| NCT00830960 | Phase 3 | Completed |
| NCT00642174 | Phase 2 | Completed |
| NCT00385944 | Phase 2 | Completed |
| NCT00097591 | Phase 3 | Completed |
Competing Products
20 competing products in Myocardial Infarction